General MedicationsINJECTIONGeneric
KINLYTIC
UROKINASE
Standard Dose
250,000 IU/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview KINLYTIC is listed in Drugs@FDA under application 021846 (BLA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient UROKINASE Form and strength INJECTABLE;INJECTION - 250,000 IU/VIAL Sponsor MICROBIX BIOSYSTEMS Submission history Latest submission status date: 2008-07-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview KINLYTIC is listed in Drugs@FDA under application 021846 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient UROKINASE Form and strength INJECTABLE;INJECTION - 250,000 IU/VIAL Sponsor MICROBIX BIOSYSTEMS Submission history Latest submission status date: 2008-07-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.